Menu

French Scientists Petition for Firm Stance Against Springer

More than 2,000 signatories urge a national consortium of French academic institutions to refuse an increase in journal subscription fees.

Apr 11, 2018
Diana Kwon

ISTOCK, LEREMYA group of researchers at the French National Center for Scientific Research (CNRS) started an online petition last weekend (April 8) to publically support Couperin.org, a national consortium representing more than 250 academic institutions in France, in its fee negotiations with academic publisher SpringerNature. More than 2,000 people have signed the petition so far.

“We are employed by the institutions members of Couperin. As such, our work will be directly affected should Springer eventually decide to enact their decision and shut down access to their recent contents,” the petition states. “However, we support the firm stance taken by Couperin and we are ready to endure this relative discomfort for as long as it will be necessary to bring Springer to acceptable propositions.”

See “French Universities Cancel Subscriptions to Springer Journals” 

Fee negotiations between Couperin.org and SpringerNature regarding one of the publisher’s platforms, Springer—which alone has more than 2,000 journals—are stuck in a stalemate. The key point of contention is a rise in subscription costs, which the consortium believes should be reduced in light of the rising proportion of expensive open-access papers.

Last month, the consortium announced that French universities and research organizations would not renew their Springer subscriptions due to this disagreement.

The publisher told The Scientist last month that it would maintain institutions’ access to its journals while in negotiations. If that agreements ends, French scientists are willing to deal with the repercussions. “No more direct access to Springer’s latest papers? No problem,” the petition states. “There are so many ways [to access papers]: institutional depositories, social networks, direct requests to the authors… We are not worried.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.